Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects

Clinical trial NCT00616655 · COMPLETED

Trial details

NCT number: NCT00616655
Sponsor: Sumitomo Pharma America, Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Generalized Anxiety Disorder

Start date: 2008-01-01
Primary completion: 2008-12-01
Enrollment: 456

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.